{"id":179566,"date":"2026-02-04T08:31:51","date_gmt":"2026-02-04T13:31:51","guid":{"rendered":"https:\/\/alphastreet.com\/india\/?p=179566"},"modified":"2026-02-04T08:31:51","modified_gmt":"2026-02-04T13:31:51","slug":"metropolis-healthcare-posts-higher-revenue-and-margins-in-q3-fy26-on-volume-growth-and-mix-improvement","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/metropolis-healthcare-posts-higher-revenue-and-margins-in-q3-fy26-on-volume-growth-and-mix-improvement\/","title":{"rendered":"Metropolis Healthcare posts higher revenue and margins in Q3 FY26 on volume growth and mix improvement"},"content":{"rendered":"\n

Metropolis Healthcare Limited (BSE: 542650 \/ NSE: METROPOLIS)<\/strong> reported higher revenue and profitability in the quarter ended December 31, 2025, supported by rising patient and test volumes, stronger B2C and B2B traction, and an improved mix toward specialty and TruHealth offerings.<\/p>\n\n\n\n

For Q3 FY26 (MHL Group), revenue increased 26% year-on-year to \u20b9406 crore. EBITDA rose 32% to \u20b995 crore, while profit after tax (excluding the exceptional impact of the new labour code) increased 63% to \u20b951 crore.<\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

Business overview<\/strong><\/h2>\n\n\n\n

Metropolis Healthcare is India\u2019s second-largest diagnostic chain, operating a network of 219 laboratories and over 4,800 patient service centres across more than 750 towns. The company offers over 4,100 tests and profiles, including advanced diagnostics in oncology, genomics, neurology and infectious diseases.<\/p>\n\n\n\n

The company operates through both organic (MHL Organic) and group (MHL Group) reporting structures, with the latter including acquisitions of Core Diagnostics, DAPIC (Dehradun), Scientific Pathology (Agra) and Ambika Pathology (Kolhapur).<\/p>\n\n\n\n

Financial performance \u2014 Q3 FY26<\/strong><\/h2>\n\n\n\n

On a Group basis, revenue rose to \u20b9406 crore from \u20b9323 crore a year earlier. EBITDA margin expanded to 23.4%, up 120 basis points year-on-year, supported by stable performance at Core Diagnostics and higher-margin contributions from acquired businesses.<\/p>\n\n\n\n

PAT (excluding exceptional items) increased to \u20b951 crore from \u20b931 crore in Q3 FY25. The exceptional item related to the impact of the new labour code was \u20b99 crore.<\/p>\n\n\n\n

On an Organic basis (excluding recent acquisitions), revenue grew 15% year-on-year to \u20b9371 crore. EBITDA margin expanded to 25.0%, up 280 basis points, reflecting operating leverage and productivity gains.<\/p>\n\n\n\n

Nine-month performance (9M FY26)<\/strong><\/h2>\n\n\n\n

For 9M FY26 (Group), revenue increased 24% to \u20b91,221 crore. EBITDA rose 21% to \u20b9293 crore, while PAT (excluding exceptional items) increased 28% to \u20b9149 crore.<\/p>\n\n\n\n

On an Organic basis, 9M FY26 revenue rose 13% to \u20b91,118 crore, with EBITDA margin improving to 25.5% from 24.5% in 9M FY25.<\/p>\n\n\n\n

Operating metrics<\/strong><\/h2>\n\n\n\n

Patient and test volumes grew 14% and 13% year-on-year, respectively, driven by deeper penetration in Tier II and Tier III markets and a favourable shift toward complex testing.<\/p>\n\n\n\n

Revenue per Test (RPT) increased 11% to \u20b9557, while Revenue per Patient (RPP) rose 10% to \u20b91,165.<\/p>\n\n\n\n

B2C revenue grew 19% year-on-year to \u20b9232 crore, while B2B revenue increased 35% to \u20b9174 crore. TruHealth and Specialty portfolios recorded growth of approximately 37% and 34%, respectively.<\/p>\n\n\n\n

Revenue mix and geography<\/strong><\/h2>\n\n\n\n

In Q3 FY26, Specialty contributed 38% of segment revenue, TruHealth 17%, Semi-Special 26% and Routine 19%. North India contributed 17% of revenue, while Tier III cities grew 16% year-on-year and accounted for 24% of overall revenue.<\/p>\n\n\n\n

Network expansion and acquisitions<\/strong><\/h2>\n\n\n\n

The company added two laboratories and 112 service centres in Q3 FY26, while closing four labs for consolidation. Its footprint expanded from around 300 towns in FY23 to approximately 750 towns.<\/p>\n\n\n\n

Recent acquisitions were integrated as planned, with stable margins at Core Diagnostics and continued outperformance from Scientific Pathology (Agra), DAPIC (Dehradun) and Ambika Pathology (Kolhapur).<\/p>\n\n\n\n

Key developments<\/strong><\/h2>\n\n\n\n

Metropolis launched a Centre of Genomics in partnership with Illumina to scale NGS-based testing and added over 300 new tests. It also expanded AI-enabled diagnostics, including AI-driven Allergy CRD and AI-verified prostate biopsy tests.<\/p>\n\n\n\n

The Board approved a 3:1 bonus issue of equity shares.<\/p>\n\n\n\n

Risks and constraints<\/strong><\/h2>\n\n\n\n

Performance remains sensitive to demand trends in preventive healthcare, pricing dynamics in diagnostics, integration of acquisitions, manpower and consumable costs, and regulatory changes including labour codes and quality standards.<\/p>\n\n\n\n

Outlook and commentary<\/strong><\/h2>\n\n\n\n

Management stated that growth was supported by higher specialty mix, digital channel scaling, and continued expansion in Tier II and Tier III markets, while maintaining focus on productivity an<\/p>\n","protected":false},"excerpt":{"rendered":"

Metropolis Healthcare Limited (BSE: 542650 \/ NSE: METROPOLIS) reported higher revenue and profitability in the quarter ended December 31, 2025, supported by rising patient and test volumes, stronger B2C and B2B traction, and an improved mix toward specialty and TruHealth offerings. For Q3 FY26 (MHL Group), revenue increased 26% year-on-year to \u20b9406 crore. EBITDA rose […]<\/p>\n","protected":false},"author":2390,"featured_media":125416,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[392,1941,5747,5],"tags":[15737,15736,15733,14580,15734,15732,15728,15726,15738,15730,15727,15731,14559,15729,15735],"class_list":["post-179566","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-earnings","category-stock-analysis","category-healthcare-stocks","category-latest","tag-b2b-diagnostics","tag-b2c-diagnostics","tag-bse-542650","tag-corporate-earnings-india","tag-diagnostic-healthcare-india","tag-metropolis-earnings","tag-metropolis-healthcare","tag-metropolis-healthcare-limited","tag-metropolis-q3-fy26","tag-metropolis-results","tag-nse-metropolis","tag-pathology-labs-india","tag-quarterly-results-india","tag-specialty-diagnostics","tag-truhealth"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":170978,"url":"https:\/\/alphastreet.com\/india\/metropolis-healthcare-q1-fy26-earnings-results\/","url_meta":{"origin":179566,"position":0},"title":"Metropolis Healthcare Q1 FY26 Earnings Results","author":"Chirag Gupta","date":"September 5, 2025","format":false,"excerpt":"Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East. Presenting below are its Q1 FY26 earnings results. \u00a0 Q1 FY26 Earnings Results Revenue: \u20b9386 crores, up 23% YoY (Q1 FY25: \u20b9313.4\u2013315.8\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Metropolis Healthcare Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-3.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-3.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-3.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-3.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-3.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/2-3.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":179667,"url":"https:\/\/alphastreet.com\/india\/metropolis-healthcare-reports-26-revenue-growth-in-q3-board-approves-31-bonus-issue\/","url_meta":{"origin":179566,"position":1},"title":"Metropolis Healthcare Reports 26% Revenue Growth in Q3; Board Approves 3:1 Bonus Issue","author":"Staff Correspondent","date":"February 5, 2026","format":false,"excerpt":"India\u2019s second-largest diagnostic chain saw net profit surge 63% on an adjusted basis as specialty testing and acquisition integrations drove volume growth. The company is continuing its \"Metropolis 3.0\" strategy to expand its footprint in Tier II and Tier III markets. Metropolis Healthcare Limited (NSE: METROPOLIS) reported a 26% year-on-year\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/10\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":148094,"url":"https:\/\/alphastreet.com\/india\/metropolis-healthcare-q4fy23-earnings-story\/","url_meta":{"origin":179566,"position":2},"title":"Metropolis Healthcare Q4FY23 Earnings Story","author":"Karan_Singh","date":"June 2, 2023","format":false,"excerpt":"Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East. Financial Results: Metropolis Healthcare Ltd. reported Total Income for Q4FY23 of \u20b9 282.5 Crores up from \u20b9 305.9 Crore year on year,\u2026","rel":"","context":"In "Earnings"","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2022\/10\/science-lab_evotec_-Macrovector.jpg?resize=700%2C400&ssl=1 2x"},"classes":[]},{"id":166983,"url":"https:\/\/alphastreet.com\/india\/metropolis-healthcare-ltd-q3fy25-15-rise-in-profits\/","url_meta":{"origin":179566,"position":3},"title":"Metropolis Healthcare Ltd Q3FY25; 15% rise in Profits","author":"Chirag Gupta","date":"February 19, 2025","format":false,"excerpt":"Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East. Financial Results: Metropolis Healthcare Ltd reported Revenues for Q3FY25 of \u20b9323.00 Crores up from \u20b9291.00 Crore year on year, a rise of\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-12.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-12.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-12.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-12.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-12.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/02\/1-12.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":156570,"url":"https:\/\/alphastreet.com\/india\/metropolis-healthcare-ltd-q2fy24-10-fall-in-profits\/","url_meta":{"origin":179566,"position":4},"title":"Metropolis Healthcare Ltd Q2FY24; 10% fall in Profits","author":"Hardik Bhandare","date":"November 22, 2023","format":false,"excerpt":"Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East. Financial Results: Metropolis Healthcare Ltd reported Revenues for Q2FY24 of \u20b9308.00 Crores up from \u20b9300.00 Crore year on year, a rise of\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-293.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-293.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-293.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-293.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-293.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2023\/11\/image-293.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":158407,"url":"https:\/\/alphastreet.com\/india\/metropolis-healthcare-ltd-q3fy24-25-fall-in-profits\/","url_meta":{"origin":179566,"position":5},"title":"Metropolis Healthcare Ltd Q3FY24; 25% fall in Profits","author":"Chirag Gupta","date":"February 5, 2024","format":false,"excerpt":"Metropolis Healthcare Limited is one of the leading Indian diagnostics companies. The Company owns a chain of diagnostic centres across India, South Asia, Africa and the Middle East. Financial Results: Metropolis Healthcare Ltd reported Revenues for Q3FY24 of \u20b9291.00 Crores up from \u20b9285.00 Crore year on year, a rise of\u2026","rel":"","context":"In "AlphaGraphs"","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-29.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-29.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-29.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-29.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-29.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/02\/image-29.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/2390"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=179566"}],"version-history":[{"count":1,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179566\/revisions"}],"predecessor-version":[{"id":179568,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/179566\/revisions\/179568"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/125416"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=179566"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=179566"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=179566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}